Cargando…
T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers
Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selec...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396988/ https://www.ncbi.nlm.nih.gov/pubmed/35997354 http://dx.doi.org/10.3390/diseases10030049 |
_version_ | 1784772035942023168 |
---|---|
author | Seraceni, Silva Zocca, Elena Cervone, Tamara Emanuela Tomassetti, Flaminia Polidori, Isabella Valisi, Massimiliano Broccolo, Francesco Calugi, Graziella Bernardini, Sergio Pieri, Massimo |
author_facet | Seraceni, Silva Zocca, Elena Cervone, Tamara Emanuela Tomassetti, Flaminia Polidori, Isabella Valisi, Massimiliano Broccolo, Francesco Calugi, Graziella Bernardini, Sergio Pieri, Massimo |
author_sort | Seraceni, Silva |
collection | PubMed |
description | Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selected 23 people in low-antibodies (Group 1, N = 8), high-antibodies (Group 2, N = 9), and negative control groups (Group 3, N = 6). SARS-CoV-2-specific humoral and cellular responses were analyzed at 8 months after two doses of Pfizer BioNTech, evaluating anti-RBD (Receptor Binding Domain) and RBD-ACE2 (Angiotensin Converting Enzyme-2) blocking antibodies in sera through a Chemiluminescence Immunoassay (CLIA) and T-cells through the IGRA test in heparinized plasma. Moreover, lymphocyte subtyping was executed by a flow cytometer. Statistical analysis was performed. Results: The data confirmed that RBD and RBD-ACE2 blocking ACE2 antibody levels of Group 1 were significantly lower than Group 2; p < 0.001. However, T-cells showed no significant difference between Group 1 and Group 2. Conclusions: This work suggests the need for new strategies for booster doses administration. |
format | Online Article Text |
id | pubmed-9396988 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93969882022-08-24 T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers Seraceni, Silva Zocca, Elena Cervone, Tamara Emanuela Tomassetti, Flaminia Polidori, Isabella Valisi, Massimiliano Broccolo, Francesco Calugi, Graziella Bernardini, Sergio Pieri, Massimo Diseases Brief Report Background: SARS-CoV-2 T-cells are crucial for long-term protection against reinfection. The aim was to demonstrate the Interferon-gamma Release Assay (IGRA) test could be useful for vaccination monitoring. Methods: In a prospective cohort of 98 vaccinated healthcare workers for SARS-CoV-2, we selected 23 people in low-antibodies (Group 1, N = 8), high-antibodies (Group 2, N = 9), and negative control groups (Group 3, N = 6). SARS-CoV-2-specific humoral and cellular responses were analyzed at 8 months after two doses of Pfizer BioNTech, evaluating anti-RBD (Receptor Binding Domain) and RBD-ACE2 (Angiotensin Converting Enzyme-2) blocking antibodies in sera through a Chemiluminescence Immunoassay (CLIA) and T-cells through the IGRA test in heparinized plasma. Moreover, lymphocyte subtyping was executed by a flow cytometer. Statistical analysis was performed. Results: The data confirmed that RBD and RBD-ACE2 blocking ACE2 antibody levels of Group 1 were significantly lower than Group 2; p < 0.001. However, T-cells showed no significant difference between Group 1 and Group 2. Conclusions: This work suggests the need for new strategies for booster doses administration. MDPI 2022-07-31 /pmc/articles/PMC9396988/ /pubmed/35997354 http://dx.doi.org/10.3390/diseases10030049 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Seraceni, Silva Zocca, Elena Cervone, Tamara Emanuela Tomassetti, Flaminia Polidori, Isabella Valisi, Massimiliano Broccolo, Francesco Calugi, Graziella Bernardini, Sergio Pieri, Massimo T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title | T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title_full | T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title_fullStr | T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title_full_unstemmed | T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title_short | T-Cell Assay after COVID-19 Vaccination Could Be a Useful Tool? A Pilot Study on Interferon-Gamma Release Assay in Healthcare Workers |
title_sort | t-cell assay after covid-19 vaccination could be a useful tool? a pilot study on interferon-gamma release assay in healthcare workers |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396988/ https://www.ncbi.nlm.nih.gov/pubmed/35997354 http://dx.doi.org/10.3390/diseases10030049 |
work_keys_str_mv | AT seracenisilva tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT zoccaelena tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT cervonetamaraemanuela tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT tomassettiflaminia tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT polidoriisabella tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT valisimassimiliano tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT broccolofrancesco tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT calugigraziella tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT bernardinisergio tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers AT pierimassimo tcellassayaftercovid19vaccinationcouldbeausefultoolapilotstudyoninterferongammareleaseassayinhealthcareworkers |